A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation.
Publication/Presentation Date
12-1-2022
Abstract
Contemporary, prospective data regarding the impact of granulocyte-colony stimulating factor (G-CSF) on outcomes after autologous hematopoietic stem cell transplantation (Auto-HSCT) in an era when stem cell grafts are more qualitatively robust are limited. Recent retrospective analyses have not supported a beneficial effect of post-transplantation G-CSF use on major outcomes after Auto-HSCT leading to strategies to delay or eliminate the use of G-CSF altogether in this context. To test the hypothesis that the infusion of consistently higher doses of stem cells (defined as ≥4 × 10
Volume
28
Issue
12
First Page
1
Last Page
831
ISSN
2666-6367
Published In/Presented At
Grosso, D., Leiby, B., Wilde, L., Carabasi, M., Filicko-O'Hara, J., O'Hara, W., Wagner, J. L., Mateja, G., Alpdogan, O., Binder, A., Kasner, M., Keiffer, G., Klumpp, T., Martinez, U. O., Palmisiano, N., Porcu, P., Gergis, U., & Flomenberg, N. (2022). A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation. Transplantation and cellular therapy, 28(12), 831.e1–831.e7. https://doi.org/10.1016/j.jtct.2022.09.012
Disciplines
Medicine and Health Sciences
PubMedID
36167307
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article